Black­stone dou­bles down on cell ther­a­py, pour­ing life (and a lot of cash) in­to a once hot biotech

Fer­Gene’s $570 mil­lion im­plo­sion ev­i­dent­ly hasn’t scared off Black­stone from cell and gene ther­a­py.

The mas­sive Wall Street in­vest­ment firm an­nounced ear­ly Mon­day a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER